Table 4.

Univariate and multivariate logistic regression analyses for serious events (model 2).^a

	Univariate		Multivariate
	Odds ratio (95% CI)	p	Odds ratio (95% CI)	p
Overweight, 25 ≤ BMI < 30 kg/m2	2.83 (0.69–11.63)	0.15	3.81 (0.79–18.33)	0.09
Obesity, BMI ≥ 30 kg/m2	4.99 (1.26–19.76)	0.02	9.14 (1.81–46.18)	0.007
Age, years	0.98 (0.95–1.01)	0.17	0.99 (0.95–1.03)	0.48
Sex	1.48 (0.57–3.80)	0.41	2.25 (0.71–7.08)	0.17
Type 2 diabetes	0.66 (0.20–2.14)	0.49	1.04 (0.21–5.15)	0.96
Arterial hypertension	0.75 (0.29–1.90)	0.54	0.88 (0.20–3.90)	0.86
Chronic respiratory diseaseb	1.42 (0.27–7.55)	0.68	1.44 (0.19–10.80)	0.72
RAAS inhibitors	0.76 (0.27–2.15)	0.61	1.13 (0.21–5.91)	0.89
Statins	0.29 (0.04–2.31)	0.24	0.12 (0.01–1.57)	0.11
HCQ/AZT treatment combinationc	0.73 (0.23–2.25)	0.59	0.40 (0.10–1.70)	0.22

Abbreviations: AZT = azithromycin. BMI = body mass index. HCQ = hydroxychloroquine. RAAS = renin-angiotensin-aldosterone system.

Bold value is statistically significant to p-value < 0.05.

^aUnivariate and multivariate associations between serious events and BMI between 18.5 and 25 kg/m² (reference), BMI between 25 and 30 kg/m², BMI ≥ 30 kg/m², age, sex, type 2 diabetes, arterial hypertension, chronic respiratory disease, RAAS inhibitors, statins and HCQ/AZT combination.

^bChronic respiratory disease: asthma, obstructive sleep apnea, chronic obstructive pulmonary disease.

^cHCQ/AZT: combination of hydroxychloroquine for 10 days and azithromycin for 5 days.